Wednesday, 14th of August 2013 |
The Lancet, Volume 376, Issue 9744, Pages 895 - 902, 11 September 2010
Published Online: 23 August 2010
Copyright © 2010 Elsevier Ltd All rights reserved.
Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial
Original Text
Feng-Cai Zhu MSc a, Prof Jun Zhang MD b, Xue-Feng Zhang MSc a, Cheng Zhou MD c, Zhong-Ze Wang MD d, Shou-Jie Huang MD b, Hua Wang MD a, Chang-Lin Yang BSc d, Han-Min Jiang BSc d, Jia-Ping Cai BSc d, Yi-Jun Wang BSc d, Xing Ai MSc a, Yue-Mei Hu MD a, Quan Tang MD a, Xin Yao MSc c, Qiang Yan MSc b, Yang-Ling Xian BSc e, Prof Ting Wu PhD b, Yi-Min Li MD e, Prof Ji Miao PhD b, Prof Mun-Hon Ng PhD b, Prof James Wai-Kuo Shih PhD b, Prof, Dr Ning-Shao Xia MD b
Summary below; full text is at http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61030-6/fulltext
Background
Seroprevalence data suggest that a third of the worlds population has been infected with the hepatitis E virus. Our aim was to assess efficacy and safety of a recombinant hepatitis E vaccine, HEV 239 (Hecolin; Xiamen Innovax Biotech, Xiamen, China) in a randomised, double-blind, placebo-controlled, phase 3 trial.
Methods
Healthy adults aged 16—65 years in, Jiangsu Province, China were randomly assigned in a 1:1 ratio to receive three doses of HEV 239 (30 μg of purified recombinant hepatitis E antigen adsorbed to 0·8 mg aluminium hydroxide suspended in 0·5 mL buffered saline) or placebo (hepatitis B vaccine) given intramuscularly at 0, 1, and 6 months. Randomisation was done by computer-generated permuted blocks and stratified by age and sex. Participants were followed up for 19 months. The primary endpoint was prevention of hepatitis E during 12 months from the 31st day after the third dose. Analysis was based on participants who received all three doses per protocol. Study participants, care givers, and investigators were all masked to group and vaccine assignments. This trial is registered with ClinicalTrials.gov, number NCT01014845.
Findings
11 165 of the trial participants were tested for hepatitis E virus IgG, of which 5285 (47%) were seropositive for hepatitis E virus. Participants were randomly assigned to vaccine (n=56 302) or placebo (n=56 302). 48 693 (86%) participants in the vaccine group and 48 663 participants (86%) in the placebo group received three vaccine doses and were included in the primary efficacy analysis. During the 12 months after 30 days from receipt of the third dose 15 per-protocol participants in the placebo group developed hepatitis E compared with none in the vaccine group. Vaccine efficacy after three doses was 100·0% (95% CI 72·1—100·0). Adverse effects attributable to the vaccine were few and mild. No vaccination-related serious adverse event was noted.
Interpretation
HEV 239 is well tolerated and effective in the prevention of hepatitis E in the general population in China, including both men and women age 16—65 years.
Funding
Chinese National High-tech R&D Programme (863 programme), Chinese National Key Technologies R&D Programme, Chinese National Science Fund for Distinguished Young Scholars, Fujian Provincial Department of Sciences and Technology, Xiamen Science and Technology Bureau, and Fujian Provincial Science Fund for Distinguished Young Scholars.
a Jiangsu Provincial Centre for Disease Control and Prevention, Nanjing, Jiangsu Province, China
b National Institute of Diagnostics and Vaccine Development in Infectious Diseases, The Key Laboratory of the Ministry of Education for Cell Biology and Tumour Cell Engineering, Xiamen University, Xiamen, China
c National Institute for the Control of Pharmaceuticals and Biological Products, Beijing, China
d Dongtai Centre for Disease Control and Prevention, Dongtai, Jiangsu Province, China
e Xiamen Innovax Biotech, Xiamen, China
Correspondence to: Dr Ning-Shao Xia, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, The Key Laboratory of the Ministry of Education for Cell Biology and Tumour Cell Engineering, Xiamen University, 422nd Siming South Road, Xiamen, 361005, China
Are three drugs for malaria better than two?
Friday, 24th of April 2020 |
Public health Interventions and epidemic intensity during the 1918 influenza pandemic
Thursday, 16th of April 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Tuesday, 17th of March 2020 |
Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications
Monday, 17th of February 2020 |
Immunization Agenda 2030
Tuesday, 11th of February 2020 |
41184496 |
www.measlesinitiative.org www.technet21.org www.polioeradication.org www.globalhealthlearning.org www.who.int/bulletin allianceformalariaprevention.com www.malariaworld.org http://www.panafrican-med-journal.com/ |